Research

Hormonal

Pioglitazone improves MASH resolution and may improve fibrosis, but is limited by side effects like weight gain and heart failure exacerbation.

Pioglitazone can resolve MASH and improve fibrosis, but it causes weight gain and fluid retention, which can worsen heart failure. It is not a first-line treatment but may be considered if other options fail and heart failure is not a concern.

GoodQualifiesHIGH confidence
Two recent meta-analyses concluded that pioglitazone is superior to placebo in achieving both MASH resolution and 1-stage improvement in fibrosis
Paolo Raggi et al. · Atherosclerosis · 2024

Why this rating

Supported by meta-analyses and RCTs, but limited by side effect profile.

Source

Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology

Paolo Raggi et al. · Atherosclerosis · 2024

DOI 10.1016/j.atherosclerosis.2024.117523

narrative_reviewCited 12×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →